Mobile website
Clinical Research
The value of iSEND immune score combined with LIPI in assessing the prognosis of non-small cell lung cancer following immunotherapy
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
[Abstract] Objective: To investigate the value of iSEND (inhaled, self-immunoregulatory, extracellular nanovesicle-based delivery) immune score combined with lung immune prognostic index (LIPI) in evaluating the prognosis of non-small cell lung cancer (NSCLC) patients undergoing immunotherapy. Methods: A retrospective analysis was conducted on the clinical data of 100 patients with advanced NSCLC who received immunotherapy from February 2018 to February 2023. The iSEND immune score and LIPI data of these patients were collected. Patients were divided into 3 groups (poor, moderate, and good) according to their iSEND and LIPI scores. Kaplan-Meier survival curves were polotted to analyze progression-free survival (PFS) among all patients and within different groups. Cox regression analysis was used to identify the risk factors affecting patient prognosis. Results: After immunotherapy, the objective response rate (ORR) was 42.00% (42/100) and the disease control rate (DCR) was 82.00% (82/100) among NSCLC patients. The ORR and DCR were lowest in the poor groups and highest in the good groups for both iSEND immune score and LIPI score, with significant differences among groups (all P < 0.01). The mPFS for all 100 NSCLC patients was 7.63 month (95% CI [7.23, 8.05]). The mPFS for the poor, moderate, and good groups in terms of iSEND immune score was 4.69, 6.58, and 8.99 months, respectively, with the good group having the longest PFS, followed by the moderate group, and the poor group (χ2 = 125.391, P < 0.000 1). Similarly, the mPFS for the poor, moderate, and good groups in terms of LIPI was 4.54, 6.39, and 8.49 months, respectively, with the good group having the longest PFS, followed by the moderate group and poor group (χ2 = 115.707, P < 0.000 1). Cox multivariate analysis identified ECOG PS > 1, distant metastasis, iSEND immune score ≥ 2, and LIPI ≥ 2 as independent risk factors affecting patient prognosis. Conclusion: iSEND immune score and LIPI can serve as valuable prognostic indicators for NSCLC patients undergoing immunotherapy, demonstrating certain clinical value.
Keywords:
Project Supported:
Clc Number:
